Infinity Pharmaceuticals, Inc. (INFI) - Get Infinity Pharmaceuticals, Inc. Report, a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will participate in Wells Fargo's Virtual Healthcare Conference and H.C. Wainwright's 23 rd Annual Global Investment Conference being held virtually.
Presentation details can be found below:
- Wells Fargo Virtual Healthcare ConferenceFormat: Fireside chat and 1-on-1 meetingsDate and Time: Fireside chat September 9 th at 2:40pm ET; 1-on-1 meetings September 9-10Webcast Link: https://kvgo.com/wells-fargo/infinity-pharmaceuticals-sept-2021
- H.C. Wainwright Virtual 23 rd Annual Global Investment ConferenceFormat: On demand presentation and 1-on-1 meetingsDate and Time: Presentation available Monday, September 13 th 7am ET; 1-on-1 meetings September 13-15 Registration Link
The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo ® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq ® and Abraxane ® in front-line TNBC and in combination with Tecentriq and Avastin ® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil ® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo ® is a registered trademark of Bristol Myers Squibb.Tecentriq ® is a registered trademark of Genentech, Inc.Abraxane ® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.Avastin ® is a registered trademark of Genentech, Inc.Doxil ® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005247/en/